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ABSTRACT
Objectives: Discrete choice experiments (DCEs) in health economics com-
monly present choice sets in an unlabeled form. Labeled choice sets are
less abstract and may increase the validity of the results. We empirically
compared the feasibility, respondents’ trading behavior, and convergent
validity between a labeled and an unlabeled DCE for colorectal cancer
(CRC) screening programs in The Netherlands.
Methods: A labeled DCE version presented CRC screening test alterna-
tives as “fecal occult blood test,” “sigmoidoscopy,” and “colonoscopy,”
whereas the unlabeled DCE version presented them as “screening test A”
and “screening test B.” Questionnaires were sent to participants and
nonparticipants in CRC screening.
Results: Total response rate was 276 (39%) out of 712 and 1033 (46%)
out of 2267 for unlabeled and labeled DCEs, respectively (P < 0.001). The
labels played a signiﬁcant role in individual choices; approximately 22%
of subjects had dominant preferences for screening test labels. The con-
vergent validity was modest to low (participants in CRC screening:
r = 0.54; P = 0.01; nonparticipants: r = 0.17; P = 0.45) largely because of
different preferences for screening frequency.
Conclusion: This study provides important insights in the feasibility and
difference in results from labeled and unlabeled DCEs. The inclusion of
labels appeared to play a signiﬁcant role in individual choices but reduced
the attention respondents give to the attributes. As a result, unlabeled
DCEs may be more suitable to investigate trade-offs between attributes
and for respondents who do not have familiarity with the alternative
labels, whereas labeled DCEs may be more suitable to explain real-life
choices such as uptake of cancer screening.
Keywords: colorectal cancer screening, discrete choice experiment, feasi-
bility, labeled alternatives, unlabeled alternatives, validity.
Introduction
Estimates of public and patients’ preferences are of great impor-
tance in informing policy decision-making and improving adher-
ence with public health-care interventions or programs [1].
Discrete choice experiments (DCEs) have become a commonly
used technique in health economics to elicit preferences. The
DCE is an attribute-based survey method for measuring beneﬁts
(utility) [2]. In a DCE, subjects are presented with a sequence of
(hypothetical) scenarios (choice sets) and are asked to choose
between two or more competing alternatives that vary along
several characteristics or attributes of interest [2]. DCEs assume
that subjects’ preferences (as summarized by their utility func-
tion) are revealed through their choices [2] (for further details,
see Bliemer and Rose [3], Hensher et al. [4], Louviere et al. [5],
and Ryan et al. [2]).
A fundamental question that arises in the application of DCE
is whether to present the choice sets in a labeled or unlabeled
form. The unlabeled form involves assigning unlabeled alterna-
tives in the choice set, such as “alternative A,” “alternative B,”
and so on. The labeled form involves assigning labels that com-
municate information regarding the alternative. In marketing
applications, labels tend to consist of brand names and logos,
which consumers have learned to associate with different product
characteristics and feelings. In the context of health economics,
labels tend to consist of generic or brand-name medications,
speciﬁc screening tests (e.g., colonoscopy, sigmoidoscopy), spe-
ciﬁc treatments (surgery vs. conservative), or other descriptors.
An advantage of assigning labels is that alternatives will be more
realistic and the choice task will be less abstract for the subject,
which add to the validity of the results. Hence, the results may
be better suitable to support decision-making at policy level.
Nevertheless, by far, most commonly applied DCEs in health
economics used unlabeled alternatives.
The aim of our study was to empirically compare the feasi-
bility, respondents’ trading behavior, and convergent validity
between a labeled and an unlabeled DCE. All of these aspects
were explored in the context of a DCE study directed at inves-
tigating population preferences for colorectal cancer (CRC)
screening programs in The Netherlands. We were convinced that
speciﬁc aspects of endoscopy (sigmoidoscopy, colonoscopy) or
fecal occult blood test (FOBT) that determine its burden could
not be totally captured by presenting an unlabeled “screening test
A” variant to patients [6]. For that very reason, we expected
differences between an unlabeled and a labeled DCE.
Theoretical Basis of Labeled and
Unlabeled DCEs
The aim of discrete choice modeling is to estimate the weights that
respondents place on attributes of alternatives. An individual
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acting rationally is expected to evaluate the set of available
alternatives and will choose that alternative that gives the greatest
relative utility [4]. Thus, an individual will choose alternative A
over B, if U (XA, Z) > U (XB, Z), where U represents the individu-
al’s indirect utility function from certain alternatives, XA repre-
sents the attributes of alternative A, XB represents the attributes of
alternative B, and Z represents the socioeconomic and other
characteristics of the individual that inﬂuence his/her utility.
Choices made in DCEs are analyzed by using random utility
theory (i.e., an error term is included in the utility function to
reﬂect the unobservable factors in the individual’s utility function)
[4]. Thus, an individual will choose alternative A over B, if V (XA,
Z) + eA > V (XB, Z) + eB, where V is the measurable component of
utility estimated empirically, and eA and eB reﬂect the unobservable
factors in the individual’s utility function of alternative A and B,
respectively (XA, XB, and Z deﬁned as above).
There are two general types of DCEs: 1) unlabeled and 2)
labeled DCEs [5]. Unlabeled DCEs use generic titles for the
alternatives (e.g., radio-imaging “A” or “B”). Labeled DCEs use
alternative-speciﬁc titles for the alternatives (e.g., “computer
tomography” or “MRI-scan” [magnetic resonance imaging]).
The number of alternatives (irrespective of whether labeled or
unlabeled) in a choice set is unrestricted from a theoretical point
of view [4]. The decision as to whether to use labeled or unla-
beled DCEs is an important one [4]. The labeled alternative itself
conveys information to respondents. This matters in choice and
other decision tasks, because 1) respondents may use labeled
alternatives to infer information that they perceive as missing;
and 2) these inferences may be (and usually are) correlated with
the random component [5]. Although we may not exactly know
what respondents ﬁnd relevant in the label for forecasting
uptake of, for example, a health-care intervention, it may be
worthwhile to ﬁnd out if respondents prefer one alternative label
to another. A labeled DCE can take effects into account, which
respondents may have learned to associate with different health-
care intervention characteristics and feelings, and, as a result,
may be more suitable to predict [6]. Unlabeled and labeled DCEs
both have their merits. If each of the labeled options has A
attributes with L levels and the choice sets are of size M, then
there are L^MA possible choice sets, assuming that all labels are
presented in a choice set and that the same label does not appear
more than once in a choice set. If the options are unlabeled, then
there are L^A possible items that can be included in each posi-
tion of each choice set. If the choice sets are of size M and we are
not going to allow the same item to appear more than once in a
choice set, then there are “L^A choose M” possible choice sets
of size M. Therefore, the designs of an unlabeled DCE can be
much smaller. For example, two alternatives with four attributes
and three levels yields 6561 (i.e., 3(2*4) = 38) possible alternative
combinations for a labeled DCE compared with “just” 81 (i.e.,
34) possible alternative combinations for an unlabeled design.
Other merits of unlabeled DCEs include that 1) they do not
require the identiﬁcation and use of all alternatives within the
universal set of alternatives, namely, the attribute levels are suf-
ﬁciently broad to represent all alternatives; 2) they might be
more robust in terms of not violating IID-assumption (i.e., error
terms are independent and identically distributed), because the
alternatives may be less correlated with the attributes as in
labeled DCEs [4]; and 3) they encourage respondents to choose
an alternative by trading-off attribute levels, which may be desir-
able from a nonmarket valuation perspective [7]. On the other
hand, merits of using labeled DCEs include that 1) they will be
more realistic and less abstract so that responses may better
reﬂect the real preference structure; and 2) they can study the
main effect of the labels.
Methods
Case Study
CRC is the most frequently occurring malignancy within the
European Union and the second leading cause of cancer related
death in the Western world [8,9]. Various countries have imple-
mented a national screening program for CRC screening to
detect CRC in an early stage or are investigating prerequisites for
implementation [10,11]. There are several screening tests eligible
for use as a population-based screening program, such as fecal
occult blood tests (FOBTs), sigmoidoscopy, or colonoscopy. This
study aimed to investigate individual preferences for CRC screen-
ing using a DCE.
DCE Design
The questionnaire design phase involved extensive background
research, expert opinions, and interviews with screened indivi-
duals. Experts (n = 3) were asked to comment on a list of test
characteristics derived from our extensive literature review.
Potential screenees (n = 40), both participants of a CRC screen-
ing program (n = 20) and screening naive individuals (n = 20),
could also comment on the list of test characteristics and rank
them in order of importance. Based on these data, we selected the
most important test characteristics. The levels for each test char-
acteristic incorporated the range of possible test outcomes based
on the current literature (for more detail on how the qualitative
data were used to select the ﬁnal test labels, attributes, and levels,
see work of Hol et al. [L. Hol, E.W. de Bekker-Grob, L. van Dam,
et al., unpubl. ms] and van Dam et al. [12]). Table 1 lists the
labels, attributes, and attribute levels chosen. The labeled CRC
screening tests (“FOBT,” “sigmoidoscopy,” and “colonoscopy”)
may evoke individual feelings, which may not be captured in the
unlabeled CRC screening tests (“CRC screening test A” and
“CRC screening test B”). Notably, the invasiveness of the alter-
native test was (indirectly) described by the levels of ﬁve
attributes: “side effects of the test,” “complication risk of the
test,” “preparation for the patient,” “location of screening,” and
“the duration of screening.” Giving directly the information
“how a sample is taken” is, in our case, totally equal to the
screening test label, “taking a sample from your motion” is equal
to FOBT, and “tube into your back passage throughout your
colon” is equal to colonoscopy. If the unlabeled DCE would
include directly this information about “how the sample is
taken” (thus, actually naming the test), then the unlabeled DCE
will be a labeled DCE as well; the attribute “how the sample is
taken” will have an interaction with all other attributes, and a
restricted design is needed to avoid implausible combinations of
attribute levels (i.e., the attribute levels are alternative speciﬁc
and, thus, a labeled DCE). Another point of notice is that the
unlabeled experiment had, for some attributes, a smaller-level
range than the feasible options in the labeled experiment. As a
result, we avoided some extreme combinations of 30 times a
screening test, resulting in a reduction in mortality from 3.0% to
2.7% in the unlabeled DCE, which added to utility balance.
The combination of the attributes and attribute levels of the
unlabeled design resulted in 2048 CRC screening test alternatives
(44 * 23). A fractional factorial design was used based on a Web
site, which contained a library of more than 200 orthogonal
arrays [13], to reduce the number of alternatives to a manageable
level of 16 alternatives in which orthogonality and level balance
were fulﬁlled. These 16 alternatives were paired up with another
orthogonal array by using the fold-over technique (i.e., cyclic
design), which caused minimal overlap between attribute levels
[14]. Each choice set (i.e., a set of available alternatives) con-
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tained two screening test alternatives and an opt-out (see Table 2
for an example). The unlabeled design had an efﬁciency of 95%
compared with an optimal choice set design, and all main effects
were uncorrelated, according to the results of an analysis using
the software of Street and Burgess [15].
Attribute levels in the labeled DCE were alternative speciﬁc. In
other words, different CRC screening test labels (FOBT, sigmoi-
doscopy, colonoscopy) were associated with different sets of
outcomes. Implausible combinations of attribute levels and labels
were minimized as a result. Furthermore, the implausible combi-
nations of the attribute levels longest screening interval with
simultaneous highest risk reduction as well as shortest screening
interval with lowest risk reduction were blocked. Optimal designs
for labeled DCEs, which require a design with two-way interac-
tions, are not available for the general case. Fortunately, SAS
software (Version 9.1, SAS Institute Inc., Cary, NC) is capable of
generating designs that are highly efﬁcient [14] in such circum-
stances. Hence, for the labeled DCE, a D-efﬁcient design was
generated with SAS software (SAS Institute, Cary, NC), which
resulted in 84 choice sets divided into 7 versions of the question-
naire (D-error 0.573). Each choice set contained two CRC screen-
ing test alternatives and an opt-out (see Table 3 for an example).
The unlabeled as well as the labeled DCE contained a domi-
nant choice set (i.e., a choice set in which one screening test
alternative is logically preferable) to assess the understanding of
the questionnaire (i.e., rationality test). Testing for internal valid-
ity should not automatically lead to deleting responses based on
“irrational” preferences although it may be a “common” prac-
tice (e.g., [16–20]). Deleting “irrational responses” may lead to
removing of valid preferences, inducing sample selection bias,
and reducing the statistical efﬁciency and power of the estimated
choice models [21]. Therefore, further sensitivity analyses were
conducted to quantitate the effect of including and excluding
“irrational” responses.
All respondents received the same prior information to the
questionnaire: an information brochure explaining different
current CRC screening tests (FOBT, sigmoidoscopy, and colonos-
copy; i.e., how the sample could be obtained) and their character-
istics (advantages and disadvantages). Both DCEs were pilot-
tested to make sure that respondents could manage the length of
the questionnaires and to check for any problems in the interpre-
tation and face validity. None of the respondents raised any
problems with understanding the questionnaires so that the pilot
test did not result in any changes to the questionnaires.
Table 1 Attribute and levels for unlabeled and labeled discrete choice experiment between three alternatives A, B, and C
Attribute Levels in unlabeled model Levels in labeled model
Reduction in mortality Options A and B: from 3.0% to 0.3%, 1.2%, 1.8%, 2.7% FOBT: from 3.0% to 1.8%, 2.3%, 2.7%
Sigmoidoscopy: from 3.0% to 0.9%, 1.5%, 1.8%
Option C (no test): from 3.0% to 3.0% Colonoscopy: from 3.0% to 0.1%, 0.5%, 0.8%
No test (Option C; base): from 3.0% to 3.0%
Frequency of screening per 10 years Options A and B: 1, 2, 5, 10 FOBT: 3, 10, 30
Sigmoidoscopy: 1, 2, 10
Option C: 0 Colonoscopy: 1, 2, 5
No test: 0
Complication risk Options A and B: none, small FOBT: none
Sigmoidoscopy: small
Option C: none Colonoscopy: small
No test: none
Location of screening Options A and B: at home, hospital FOBT: at home
Sigmoidoscopy: hospital
Option C: none Colonoscopy: hospital
No test: none
Screening duration Options A and B: 10, 30, 60, 90 min FOBT: 30 min
Sigmoidoscopy: 15 min
Option C: 0 min Colonoscopy: 105 min
No test: 0 min
Preparation for patient Options A and B: none, enema, no fasting, drinking 0.75l + fasting,
drinking 4l + fasting
FOBT: none
Sigmoidoscopy: enema, no fasting
Option C: none Colonoscopy: drinking 4l + fasting
No test: none
Side effects of screening Options A and B: none, mild pain FOBT: none
Sigmoidoscopy: mild pain
Option C: none Colonoscopy: mild pain
No test: none
FOBT, fecal occult blood test.
Table 2 An example of an unlabeled choice set
Screening test A (A) Screening test B (B)
No screening
test (C)
Preparation None Enema, no fasting None
Location At home Hospital None
Pain None Mild pain None
Complication risk None Small None
Mortality risk of colorectal cancer decrease From 3% to 2.7% From 3% to 1.8% Remain 3%
Frequency of screening test in the next 10 years 10¥ 5¥ 0¥
Time duration (min) 10 30 0
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Study Sample and Elicitation Mode
The questionnaires were sent by mail to subjects who had
recently participated in a regional call–recall CRC screening
program (unlabeled n = 212; labeled n = 769) and to randomly
selected screening naive subjects of the same region (Groot-
Rijnmond) (unlabeled n = 500; labeled n = 1498). It was not
possible to directly calculate the statistical power to inform the
sample size for a choice experiment. Other studies showed that
a sample size of 42 to 208 respondents was sufﬁcient to answer
16 unlabeled choice sets [22–24]. A larger number of labeled
than unlabeled DCEs were distributed to potential respondents
because the design of the labeled DCE, which included
alternative-speciﬁc parameters, meant that more coefﬁcients
would be included in the model to be estimated. A larger sample
size would mean that it is possible to achieve more precise
estimation of these parameters. All respondents were between
50 and 74 years of age. Besides the choice sets, the question-
naires also included background variables of respondents such
as age, sex, endoscopy (i.e., sigmoidoscopy or colonoscopy)
experience, familiarity with CRC because of cases in family or
friends, and standardized questions (EQ-5D) to measure self-
reported health state. A reminder was sent to nonresponders 4
weeks later.
Analyses
Chi-square and Student t-tests were used to assess the differences
between the characteristics of respondents of the unlabeled and
labeled DCEs (for participants in CRC screening and for screen-
ing naive respondents separately).
To assess feasibility, we determined the response rate, ratio-
nality test outcome, missing values, and the self-rated ease of the
task. We used chi-square tests to compare differences in these
aspects of feasibility.
Both DCEs were analyzed by using multinomial logit regres-
sion models, in which the unlabeled DCE had generic parameters
and the labeled DCE had alternative speciﬁc parameters. These
models were implemented in SAS software (Version 9.1). A
priori, we expected all attributes to be important and that all
attributes would have a negative effect on utility except for
“mortality reduction.”
To assess the degree of trading behavior, we tested for domi-
nant preferences (i.e., if respondents based their responses
entirely on one speciﬁc attribute or label (one speciﬁc CRC
screening test)). Chi-square tests were used to assess differences
between both DCEs for participants in CRC screening and for
screening naive respondents separately.
Finally, relative utility values for different screening test pro-
ﬁles were determined based on the weights that respondents
placed on the attributes of alternatives. The total utility value
of a screening test proﬁle was equal to the sum of the coefﬁ-
cient weights of its attribute levels [25–28]. The agreement
between the labeled and unlabeled DCE outcomes depends
strongly on the scale of both DCEs. In DCEs, the scale is not
identiﬁed, and everything that depends on the scale is not reli-
able. Only measures based on correlation are really informa-
tive. Therefore, convergent validity between both variants was
assessed by determining the degree of agreement by means of
Pearson correlations (r). Noteworthy, perfect agreement only
exists if the relative utility outcomes between unlabeled and
labeled DCE lie along the line of equality, whereas perfect
correlation (i.e., strength of a relation between the two
approaches) exists if the relative utility outcomes lie along any
straight line [29].
Results
The total response rate was 276 (39%) out of 712 and 1033
(46%) out of 2267 for unlabeled and labeled DCE, respectively
(P < 0.001). In total, 4 (1%) out of 276 respondents and 30 (3%)
out of 1033 respondents, who missed responses to three or more
DCE questions, were excluded for further analyses. Of the
respondents to the unlabeled DCE, 44% came from the CRC
screening group and 56% from the screening naive group; this
was 53% and 47% for the labeled DCE. For this imbalance to be
corrected, all further analyses were focused on the CRC screen-
ing group and screening naive group separately. Respondents did
not differ with respect to mean age, sex, and endoscopy experi-
ence (P > 0.13) for unlabeled and labeled variants, respectively
(Table 4).
Feasibility
The response rate was higher for the labeled DCE than for the
unlabeled DCE (Table 5). The labeled DCE especially led to a
higher response rate for the CRC screening group (71% vs. 57%,
P < 0.001; 33% vs. 31% for screening naive group, P = 0.51).
An equal proportion of respondents of the CRC screening group
passed the rationality test irrespective of DCE approach (91% vs.
91%; P = 0.96). Nevertheless, more respondents failed the ratio-
nality test with the labeled design in the screening naive group
(18% vs. 5% for unlabeled design; P < 0.001). There was an
equal proportion missing values of 1% for both DCEs irrespec-
tive of the response group. Most respondents indicated that they
had no difﬁculties in completing the DCE task, and the groups
did not perceive the task differently (P = 0.28 and P = 0.61 for
CRC screening group and screening naive group, respectively)
(Table 5).
DCE Results
The effects (i.e., positive or negative direction) of the coefﬁcients
of both DCEs were consistent with a priori expectations (and
showed therefore theoretical validity), except for the attribute
Table 3 An example of labeled choice set
Sigmoidoscopy
(A)
FOBT
(B)
No screening
test (C)
Preparation Enema, no fasting None None
Location Hospital At home None
Pain Mild pain None None
Complication risk Small None None
Mortality risk of colorectal cancer decrease From 3% to 0.9% From 3% to 2.3% Remain 3%
Frequency of screening test in the next 10 years 2¥ 10¥ 0¥
Time duration (min) 15 30 0
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“frequency of screening” in the unlabeled approach (details
in the Appendix at: http://www.ispor.org/Publications/value/
ViHsupplementary/ViH13i2_deBekkerGrob.asp). The positive
coefﬁcient of this attribute in the unlabeled DCE suggests that
respondents preferred a higher frequency of screening over a
lower frequency of screening per 10 years.
Regarding the unlabeled DCE, all attributes except the
attribute “location of screening” proved to be important for
preferences of both groups for CRC screening tests (see Appendix
at: http://www.ispor.org/Publications/value/ViHsupplementary/
ViH13i2_deBekkerGrob.asp). The positive constant term sug-
gests that respondents from the CRC screening group preferred
“CRC screening test” over “no CRC screening test” if all other
attributes were set to zero.
Regarding the labeled DCE, all attributes proved to be
important for preferences of both groups for CRC screening
tests (see Appendix at: http://www.ispor.org/Publications/value/
ViHsupplementary/ViH13i2_deBekkerGrob.asp; note that, ﬁve
out of seven attributes (i.e., location of screening, preparation for
the patient, side effects of screening, complication risk, and screen-
ing duration) were attributes that had one alternative speciﬁc
level. As a result, their coefﬁcients were caught up in the coefﬁcient
of the alternative label). The positive and signiﬁcant alternative
speciﬁc constants suggest that the CRC screening group had a
positive attitude toward “CRC screening test” over “no CRC
screening test,” irrespective of the screening test used (i.e., FOBT,
sigmoidoscopy, or colonoscopy). This phenomenon was also seen
in the screening naive group although the alternative speciﬁc
constant of FOBT did not signiﬁcantly differ from the base level
“no CRC screening test” (P = 0.16).
The outcomes of the sensitivity analyses, which excluded the
respondents who failed the rationality test, were quite similar
whether or not these irrational responses were retained (data not
shown). To avoid the removal of valid preferences, the induction
of sample selection bias, and the unnecessary reduction of the
statistical efﬁciency and power of the estimated choice models,
we included the responses of respondents who failed the ratio-
nality test in all our further analyses.
Table 4 Characteristics of respondents
Variable
Unlabeled DCE
(n = 272)
Labeled DCE
(n = 1003)
Unlabeled
vs. labeled
DCE (P-value)
Group (n %) 0.01
CRC screening respondents 120 (44.1) 529 (52.7)
Screening naive respondents 152 (55.9) 474 (47.3)
Age (mean SD)
CRC screening respondents 62.2 (6.3) 61.0 (7.0) 0.13
Screening naive respondents 59.9 (5.7) 60.9 (6.6) 0.29
Sex (male; n %)
CRC screening respondents 59 (49.2) 277 (52.4) 0.53
Screening naive respondents 74 (48.7) 238 (50.2) 0.74
Endoscopy experience (n %)
CRC screening respondents 0.26
Yes 64 (53.3) 255 (48.2)
No 54 (45.0) 271 (51.2)
Unknown 2 (1.7) 3 (0.6)
Screening naive respondents 0.43
Yes 33 (21.7) 119 (25.1)
No 117 (77.0) 353 (74.5)
Unknown 2 (1.3) 2 (0.4)
CRC, colorectal cancer; DCE, discrete choice experiment.
Table 5 Differences in several aspects of feasibility
CRC screening subjects CRC screening naive subjects
Unlabeled Labeled
P-value*
Unlabeled Labeled
P-value*n (%) n (%) n (%) n (%)
Response rate <0.001 0.51
Response 121 (57.1) 545 (70.9) 155 (31.0) 488 (32.6)
No response 91 (42.9) 224 (29.1) 345 (69.0) 1010 (67.4)
Rationality test 0.96 <0.001
Passed 110 (90.9) 496 (91.0) 148 (95.5) 400 (82.0)
Failed 11 (9.1) 49 (9.0) 7 (4.5) 88 (18.0)
Missing values 0.10 0.28
Missing value 15 (0.8) 79 (1.3) 13 (0.5) 37 (0.8)
No missing value 1777 (99.2) 5873 (98.7) 2371 (99.5) 4763 (99.2)
Ease of task as perceived by subject 0.28 0.61
Very easy 14 (11.7) 91 (17.2) 41 (27.0) 122 (25.7)
Easy 60 (50.0) 258 (48.8) 66 (43.4) 216 (45.6)
Average 31 (25.8) 130 (24.6) 38 (25.0) 102 (21.5)
Difﬁcult 12 (10.0) 32 (6.0) 5 (3.3) 25 (5.3)
Very difﬁcult 0 (0.0) 4 (0.8) 0 (0.0) 3 (0.6)
Missing values 3 (2.5) 14 (2.6) 2 (1.3) 6 (1.3)
*Difference between respondents unlabeled and labeled DCE.
CRC, colorectal cancer; DCE, discrete choice experiment.
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Respondents’ Trading Behavior
The labeled DCE led to more dominant preferences (i.e.,
responses entirely based on one speciﬁc attribute or label)
(Table 6). This difference was signiﬁcant for both the CRC
screening group (41% vs. 21% for unlabeled DCE; P < 0.001)
and the screening naive group (39% vs. 24% for unlabeled DCE;
P = 0.001). This difference was caused by the test labels; 24%
and 21% of the CRC screening and screening naive respondents,
respectively, had dominant preferences for screening test labels.
Table 6 also shows that the attributes of both DCEs did not make
the difference in the proportion of dominant preferences
(0.07 < P < 0.77).
Convergent Validity
Based on the coefﬁcients of the multinomial logit regression
models of the unlabeled and labeled DCE (see Appendix at:
http://www.ispor.org/Publications/value/ViHsupplementary/
ViH13i2_deBekkerGrob.asp), Figure 1 plots the difference in
relative utility values for different realistic CRC screening pro-
grams for CRC screening naive and CRC screening respondents,
respectively (see Table 7 for more details about the total relative
utility scores). By using Pearson correlations, the convergent
validity between unlabeled and labeled DCEs was found to be
low for screening naive respondents (r = 0.17; P = 0.45) but
modest for respondents with screening experience (r = 0.54;
P = 0.01). The regression comparison between unlabeled (inde-
pendent variable) and labeled DCEs (dependent variable) showed
a scaling as well as a shift phenomenon. The intercept was 0.99
(P < 0.01) and 0.90 (P < 0.01), and the scaling factor was 0.19
(P = 0.45) and 0.51 (P = 0.01) for screening naive respondents
and respondents with screening experience, respectively. Respon-
dents reacted about 0.19 or half as strong to the labeled
attributes. Taking the attribute levels of frequency into account
(i.e., ignoring the relative utility values of the attribute “fre-
quency of screening”), we found that the strength of the relation
between both approaches was reasonably good for screening
naive respondents (r = 0.71; P = 0.03; and r = 0.53; P = 0.07
for low and high frequency levels, respectively) and very good
for respondents with screening experience (r = 0.93; P < 0.001;
and r = 0.95; P < 0.001 for low and high frequency levels,
respectively).
Discussion
This study shows that it is feasible to use realistic alternatives in
labeled DCEs in a health-care context. The labeled DCE led to a
Table 6 Differences in respondents’ trading behavior
CRC screening subjects Screening naive subjects
Unlabeled
(n = 120)
Labeled
(n = 529)
P-value*
Unlabeled
(n = 152)
Labeled
(n = 474)
P-value*n (%) n (%) n (%) n (%)
Trading behavior
In general <0.001 0.001
Dominant preferences 25 (20.8) 219 (41.4) 37 (24.3) 183 (38.6)
Nondominant preferences 92 (76.7) 310 (58.6) 108 (73.7) 280 (59.1)
No test at all 3 (2.5) 2 (0.4) 3 (2.0) 11 (2.3)
Dominant preferences for
Mortality reduction 22 (18.3) 91 (17.2) 0.77 36 (23.7) 81 (14.1) 0.07
Frequency 0 3 (0.6) 0.41 0 4 (0.8) 0.26
Alternative n.a. 125 (23.6) n.a. 98 (18.4)
*Difference between respondents unlabeled and labeled DCE.
CRC, colorectal cancer; DCE, discrete choice experiment; n.a., not applicable.
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Figure 1 (a) Correlation between the relative utility values of screening naive
respondents for different screening tests based on the labeled and unlabeled
DCE (Pearson correlation 0.17; P = 0.45). (b) Correlation between the relative
utility values of CRC screening subjects for different screening tests based on
the labeled and unlabeled DCE (Pearson correlation 0.54; P = 0.01). CRC,
colorectal cancer; DCE, discrete choice experiment; FOBT, fecal occult blood
test.
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higher response rate, especially for the CRC screening group who
had familiarity with the context. Nevertheless, more respondents
who were not familiar with the context failed the rationality
test with the labeled design. The inclusion of labels appeared to
play a signiﬁcant role in individual choices, and increased non-
trading behavior. The convergent validity between both DCE
variants was low but better for respondents with CRC screening
experience.
In health economics, there are no previous publications
directly comparing labeled and unlabeled DCEs empirically. Nev-
ertheless, a DCE in ecological economics considered the effects of
employing a labeled rather than an unlabeled DCE [30]. That
study showed that the inclusion of alternative-speciﬁc labels
reduced the attention that respondents gave to the attributes (i.e.,
increased nontrading behavior). This is in line with our study,
which showed that 24% and 21% of the CRC screening expe-
rienced and screening naive respondents, respectively, only
focused at the screening test labels. The ecological economics
study also demonstrated convergent validity between a labeled
and an unlabeled DCE contrary to our study.
In line with the focus of this article, the results of the unla-
beled and labeled DCEs are only described brieﬂy (for further
detail information about the practical outcomes of these DCEs
for CRC screening practice, see work of van Dam et al. [12] and
Hol et al. [unpubl. ms.]). The respondents in our labeled experi-
ment are actually getting more and partly different information
than in the unlabeled experiment, particularly if they have had
experience of one of the options. This might be a possible expla-
nation for the differences in our outcomes between the screening
naive and CRC screening respondents. Note that, if the reader
wants to compare the beta-coefﬁcients of CRC screening respon-
dents and screening naive respondents directly (see Appendix
at: http://www.ispor.org/Publications/value/ViHsupplementary/
ViH13i2_deBekkerGrob.asp), it should be clear that scale effects
might be an issue (for more detail information, see the work of
Swait and Louviere [31]).
The positive direction (effect) of the attribute “frequency of
screening per 10 years” in the unlabeled approach (see Appendix
at: http://www.ispor.org/Publications/value/ViHsupplementary/
ViH13i2_deBekkerGrob.asp) seems to be inconsistent with
utility theory. Nevertheless, these “irrational” responses may be
explained by respondents making additional assumptions or
bringing additional information to the choice [32,33]. As Ryan
et al. [34] provided, evidence that respondents assumed tests
with higher costs would be of higher quality. Respondents in our
study might associate higher frequency of screening with a more
effective test. The differences in preferences for screening fre-
quency between the two DCE approaches demonstrate the
importance of continuing research into the biases present across
these elicitation methods. Mixed methods may be useful to get
more insight into the internal validity of the DCEs. Qualitative
techniques, such as the think-aloud technique, may show that
seemingly “irrational” choice behavior may not be so irrational
after all [34].
The predominant use of unlabeled experiments in health care
may be a result of the perception that labeled experiments are
difﬁcult to construct. The design of a labeled DCE does generally
mean that a larger sample size is required because it is assumed
that, most of time, there are interactions between the alternative
label and the attributes. Indeed, this may not be feasible in a
health-care setting (e.g., the target group of patients or medical
specialists is too small). Nevertheless, this is the case not only for
labeled DCE but also for unlabeled DCE in which all (two-way)
interactions between attributes are taken into account. Unlabeled
DCEs in which all (two-way) interactions between attributes are
taken into account may be even much larger then a labeled DCE
because, in a labeled DCE, many characteristics can be com-
pressed in one label, whereas in an unlabeled DCE, all possible
interactions should be taken into account.
Another explanation for the predominant use of unlabeled
experiments in health care may be that labeled DCEs in health
care are not necessary (yet). Although it is not clear why labeled
DCEs in health economics are rarely used, it has to be clear that
the design should be made to ﬁt the research objectives and not
the other way around. If the alternative labels are expected to
have important differences, then it may be preferable to use a
Table 7 Relative utility scores for realistic CRC screening programs
Realistic CRC screening program
(test invasiveness* / mortality
risk decreases from 3% to . . . % /
frequency per 10 years)
Relative utility score
CRC screening respondents CRC screening naive respondents
Unlabeled DCE Labeled DCE Unlabeled DCE Labeled DCE
Sigmo / 1.8% / 1 0.97 1.57 0.56 1.54
Sigmo / 1.5% / 1 1.23 1.87 0.88 1.63
Sigmo / 0.9% / 1 1.75 2.18 1.52 2.13
Sigmo / 1.8% / 2 1.21 1.57 0.84 1.38
Sigmo / 1.5% / 2 1.47 1.87 1.16 1.47
Sigmo / 0.9% / 2 1.99 2.18 1.80 1.97
Sigmo / 1.8% / 10 1.24 1.09 0.89 0.57
Sigmo / 1.5% / 10 1.50 1.39 1.21 0.66
Sigmo / 0.9% / 10 2.02 1.70 1.85 1.16
Colono / 0.8% / 1 0.96 1.54 0.74 1.23
Colono / 0.5% / 1 1.22 1.74 1.06 1.34
Colono / 0.1% / 1 1.57 1.93 1.49 1.52
Colono / 0.8% / 2 1.20 1.67 1.02 1.23
Colono / 0.5% / 2 1.46 1.87 1.34 1.34
Colono / 0.1% / 2 1.81 2.06 1.77 1.52
Colono / 0.8% / 5 1.29 1.18 1.14 0.57
Colono / 0.5% / 5 1.54 1.38 1.46 0.68
Colono / 0.1% / 5 1.90 1.57 1.89 0.86
FOBT / 2.7% / 10 0.80 1.09 0.81 0.75
FOBT / 2.3% / 10 1.41 1.27 1.24 0.89
FOBT / 1.8% / 10 1.84 1.73 1.77 1.33
*Each type of test (sigmoidoscopy, colonoscopy, FOBT) had one ﬁxed level for the following ﬁve attributes: complication risk, location of screening, screening duration, preparation for the patient,
and side effects of screening; see Table 1 for more detailed information.
CRC, colorectal cancer; DCE, discrete choice experiment; FOBT, fecal occult blood test.
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labeled DCE design. Underestimating the role of the alternative
labels may lead to worse or even wrong predictions of alterna-
tives people actually prefer. On the other side, if the objective is
to estimate attribute values, it may be desirable to use an unla-
beled DCE to reduce nontrading behavior because of alternative
labels.
This study had some limitations. First, we conducted two
DCEs in two samples. It might have been preferable (from a
theoretical point of view) to conduct the two DCEs in the same
group of respondents (i.e., all respondents ﬁlled in one DCE, and
then the other DCE; sequence in random order). Nevertheless,
that was not possible because of the respondent burden. As a
result, we cannot directly compare the absolute values of the
utility levels for the attributes and tests. Second, the design of
both DCEs was not exactly the same. The combination of
d-efﬁciency criteria and the use of alternative speciﬁc and generic
attribute levels in the labeled and unlabeled DCE, respectively,
resulted in different choice sets presented to the respondents. We
have no reason to believe that this has inﬂuenced the results to a
large extent. Third, testing the convergent validity between unla-
beled and labeled DCE was based on comparison of the total
utility of alternatives. The labeled DCE had ﬁve attributes with
one alternative speciﬁc level. Therefore, a direct comparison of
the coefﬁcients of the attributes (taking scale factor into account)
was not possible. Fourth, two attribute levels regarding the
alternative-speciﬁc attribute “frequency” of FOBT (3 and 30
times screening per 10 years) were not presented in the unlabeled
DCE. Therefore, we could only include three total utility scores
of (hypothetical) CRC screening programs with FOBT-test in our
convergent validity test between both DCE variants.
Conclusion
This study provides important insights in the feasibility and
difference in results from labeled and unlabeled DCEs. The inclu-
sion of labels appeared to play a signiﬁcant role in individual
choices but reduced the attention respondents give to the
attributes. There was low convergent validity between both DCE
variants largely because of different preferences for screening
frequency. The choice for a labeled or unlabeled DCE may
depend on the type of respondents and the research question.
Unlabeled DCEs may be more suitable to investigate trade-offs
between attributes and for respondents who do not have famil-
iarity with the alternative labels, whereas labeled DCEs may be
more suitable to explain real life choices such as uptake of cancer
screening.
Source of ﬁnancial support: Grant support was from the Dutch Cancer
Society (KWF; EMCR 2006-3673, and EMCR 2008-4117).
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